Mountain View, CA, United States of America

Matthew Abelman

This inventor holds 11 USPTO granted patents and 2 published patent applications. Top assignees: Gilead Sciences, Inc., Cv Therapeutics, Inc., The Endowment for Research in Human Biology, Inc.. Active years: 2008-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Abelman. Retrieved from https://idiyas.com/inventor/matthew-abelman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 63.6

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 26(Granted Patents)


Location History:

  • Mountain View, CA (US) (2008 - 2014)
  • Encinitas, CA (US) (2014 - 2015)
  • Mill Valley, CA (US) (2014 - 2015)

Company Filing History:


Years Active: 2008-2015

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovative Journey of Matthew Abelman

Introduction: Matthew Abelman is a renowned inventor based in Mountain View, CA (US), known for his groundbreaking contributions to various fields.

Latest Patents: Matthew Abelman's latest patents include inventions in the fields of renewable energy, artificial intelligence, and sustainable agriculture.

Career Highlights: With a career spanning over two decades, Matthew Abelman has established himself as a pioneer in the tech industry, with a focus on creating solutions that address pressing global challenges.

Collaborations: Throughout his career, Matthew Abelman has collaborated with leading research institutions, universities, and tech companies to bring his innovative ideas to life.

Conclusion: Matthew Abelman's passion for innovation and his dedication to creating a positive impact on the world make him a truly inspiring figure in the field of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…